Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 6, 2023; 11(1): 218-224
Published online Jan 6, 2023. doi: 10.12998/wjcc.v11.i1.218
Published online Jan 6, 2023. doi: 10.12998/wjcc.v11.i1.218
Pembrolizumab-induced psoriatic arthritis treated with disease-modifying anti-rheumatic drugs in a patient with gastric cancer: A case report
Sehan Kim, Jong Hee Sun, Hongsik Kim, Hee Kyung Kim, Yaewon Yang, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju 28644, South Korea
Jun Su Lee, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea
In Ah Choi, Hye Sook Han, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju 28644, South Korea
Author contributions: Kim S, Sun JH, and Kim H contributed to manuscript writing and data collection; Kim HK, Yang Y, Lee JS, and Choi IA contributed to manuscript editing and data collection; Han HS contributed to conceptualization and supervision; all authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this case report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CAER Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hye Sook Han, MD, Professor, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, No. 1 Chungdae-ro, Seowon-gu, Cheongju 28644, South Korea. hyesukhan@chungbuk.ac.kr
Received: October 16, 2022
Peer-review started: October 16, 2022
First decision: November 4, 2022
Revised: November 10, 2022
Accepted: December 16, 2022
Article in press: December 16, 2022
Published online: January 6, 2023
Processing time: 80 Days and 18.5 Hours
Peer-review started: October 16, 2022
First decision: November 4, 2022
Revised: November 10, 2022
Accepted: December 16, 2022
Article in press: December 16, 2022
Published online: January 6, 2023
Processing time: 80 Days and 18.5 Hours
Core Tip
Core Tip: Although immune checkpoint inhibitors are being used increasingly and widely, a fair percentage of patients treated with these drugs experience immune-related adverse events (irAEs). Arthralgia and skin lesions are among the most frequent irAEs. However, rheumatic irAEs are underreported and/or misclassified and have been poorly characterized. These rheumatic irAEs are different in simple arthralgia or cutaneous irAEs that they may be requiring long-term management and disease-modifying anti-rheumatic drugs in severe or refractory case. We report a first case of pembrolizumab-induced psoriatic arthritis that was treated with tumor necrosis factor-α inhibitors in a patient with gastric cancer and discuss the treatment course.